QUÉBEC CITY, May 23,
2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX: AEZ) (the "Company") today announced that the
following posters will be presented on AEZS-108, the Company's lead
oncology compound, at the upcoming American Society of Clinical
Oncology ("ASCO") annual meeting, which will be held May 31 to June 4, 2013, in Chicago.
| Abstract #
5062: |
"A Phase 1 Dose Escalating Trial of AEZS-108 in Taxane- and
Castration-Resistant Prostate Cancer", J. Pinski, A.V. Schally,
D. Tsao-Wei, T.B. Dorff, S. Groshen, S. Xiong, D. Quinn, Y.
Tai, J. Engel, S.V. Liu. |
| Presenter: |
Jacek Pinski, MD, PhD, USC Norris Comprehensive Cancer Center,
California |
| Date & Time: |
Monday, June 3, 2013, from 8:00 am to 11:45 am (central) |
| Venue: |
S Hall 2, McCormick Place, Chicago
|
| Abstract # TPS
11124: |
"A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy
Refractory Triple-Negative (ER/PR/HER2-Negative) LHRH-R Positive
Metastatic Breast Cancer", S. Buchholz, J.B. Engel, A.V.
Schally, S. Seitz, O. Ortmann, G. Emons, R.L. Mahtani, S.
Glück, C. Vogel, A.J. Montero. |
| Presenter: |
Stefan Buchholz, MD, Medical Center University of Regensburg,
Germany |
| Date & Time: |
Monday, June 3, 2013, from 1:15 pm to 5:00 pm (central) |
| Venue: |
S Hall 2, McCormick Place, Chicago |
A third abstract (# e15596) on AEZS-108, "A Case Report of a
Long-Term Response in a Patient with Urothelial Cancer (UC) Treated
with AEZS-108", G. L. Fernandez,
A. V. Schally, T. Koru-Sengul, M. Jorda, J. R. Merchan, A. M.
Flores, N. L. Block, M.
Manoharan, J. Engel, is currently available online on ASCO's
website, but will not be presented during a poster session. The
abstract reports on the first patient with LHRH-R positive UC
treated with AEZS-108 in an ongoing Phase 1 clinical trial.
About AEZS-108 (doxorubicin peptide conjugate)
AEZS-108 represents a new targeting concept in oncology using a
hybrid molecule composed of a synthetic peptide carrier and a
well-known chemotherapy agent, doxorubicin. AEZS-108 is the first
intravenous drug in advanced clinical development that directs the
chemotherapy agent specifically to LHRH-receptor expressing tumors,
resulting in more targeted treatment with less damage to healthy
tissue. The product has successfully completed Phase 2 studies for
the treatment of ovarian and endometrial cancer and the Company is
currently initiating a Phase 3 trial in endometrial cancer under a
Special Protocol Assessment. AEZS-108 is also in Phase 2 trials in
triple-negative breast cancer, prostate cancer and bladder cancer.
AEZS-108 has been granted orphan drug designation by the FDA and
orphan medicinal product designation from the European Medicines
Agency for the treatment of ovarian cancer. Aeterna Zentaris owns
worldwide rights to AEZS-108.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. For more information, visit www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.